Yesim Gokmen-Polar

List of Publications by Year
in descending order

106 papers	1,885 citations	218677 26 h-index	276875 41 g-index
106 all docs	106 docs citations	106 times ranked	3333 citing authors

#	Article	IF	Citations
1	Is conservative management of ductal carcinoma in situ risky?. Npj Breast Cancer, 2022, 8, 55.	5.2	6
2	Protein Profiling of Breast Cancer for Treatment Decision-Making. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 73-81.	3.8	4
3	Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast. British Journal of Cancer, 2021, 124, 1150-1159.	6.4	11
4	CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. Scientific Reports, 2021, 11, 4691.	3.3	53
5	Thymic Carcinomas and Second Malignancies: A Single-Center Review. Cancers, 2021, 13, 2472.	3.7	2
6	Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type. Oncotarget, 2021, 12, 1178-1186.	1.8	6
7	ColoType: a forty gene signature for consensus molecular subtyping of colorectal cancer tumors using whole-genome assay or targeted RNA-sequencing. Scientific Reports, 2020, 10, 12123.	3.3	22
8	Abstract P2-10-06: Ethnicity-dependent alternative RNA splicing variations of estrogen receptor in breast cancer. , 2020, , .		0
9	EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptorâ€“Positive Breast Cancer. Clinical Breast Cancer, 2019, 19, 17-26.e8.	2.4	7
10	Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. Journal of Clinical Oncology, 2019, 37, 3484-3492.	1.6	30
11	Ductal carcinoma in situ of breast: update 2019. Pathology, 2019, 51, 563-569.	0.6	43
12	Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptorâ€“Positive, Early Breast Cancer. JNCI Cancer Spectrum, 2019, 3, pkz051.	2.9	1
13	Splicing factor <scp>ESRP</scp> 1 controls <scp>ER</scp> â€positive breast cancer by altering metabolic pathways. EMBO Reports, 2019, 20, .	4.5	48
14	TP53 Status and Estrogen Receptor-Beta in Triple-Negative Breast Cancer: Company Matters. Journal of the National Cancer Institute, 2019, 111, 1118-1119.	6.3	8
15	Three-dimensional imaging and quantitative analysis in CLARITY processed breast cancer tissues. Scientific Reports, 2019, 9, 5624.	3.3	45
16	EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer. Breast, 2019, 43, 74-80.	2.2	7
17	HSF1 as a Cancer Biomarker and Therapeutic Target. Current Cancer Drug Targets, 2019, 19, 515-524.	1.6	79
18	Abstract P4-08-17: Expression score (Escore) for the prediction of likelihood of recurrence of DCIS. , 2019, , .		0

#	Article	IF	Citations
19	Abstract P5-04-13: Splicing factorESRP1controls ER-positive breast cancer progression by altering metabolic pathway genes. , 2019, , .		1
20	CMS-PDX: A 20-gene genomic panel to predict consensus molecular subtypes in patient-derived xenografts (PDX) of colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 598-598.	1.6	0
21	ColotypeR gene signature predicts response to cetuximab in colorectal cancer metastases.. Journal of Clinical Oncology, 2019, 37, 599-599.	1.6	0
22	Abstract 2109: A novel role forESRP1in regulating proliferation in therapy-resistant ER-positive breast cancer. , 2019, , .		0
23	The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell, 2018, 33, 244-258.e10.	16.8	270
24	Single-cell heterogeneity in ductal carcinoma in situ of breast. Modern Pathology, 2018, 31, 406-417.	5.5	41
25	Treatment of thymic malignanciesâ€"the way forward. Mediastinum, 2018, 2, 17-17.	1.1	0
26	P1.14-17 Identification of Molecular Subtypes of Thymic Epithelial Tumors and Novel Treatments Using a Computational Biological Model. Journal of Thoracic Oncology, 2018, 13, S606.	1.1	0
27	Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer. PLoS ONE, 2018, 13, e0204658.	2.5	11
28	ColotypeR: A tool to classify colon cancers by consensus molecular subtype and subtype-specific risk of recurrence.. Journal of Clinical Oncology, 2018, 36, 632-632.	1.6	1
29	Abstract 2695: Quantitative phosphoproteome analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor-positive breast cancer. , 2018, , .		0
30	Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313).. Journal of Clinical Oncology, 2017, 35, 529-529.	1.6	2
31	Abstract P1-06-02: Impact of heterogeneity of DCIS on immune cell infiltrations. , 2017, , .		0
32	Phosphopeptide mapping of DLC1 in ER+ breast cancer reveals AMOTL2, a key hippo pathway component, as an important target.. Journal of Clinical Oncology, 2017, 35, 11592-11592.	1.6	0
33	EarlyR genomic signature to predict pathological complete response following neoadjuvant anthracycline-taxane chemotherapy in estrogen-receptor positive (ER+) breast cancer.. Journal of Clinical Oncology, 2017, 35, 579-579.	1.6	1
34	Abstract 1226: Targeting BTK family in ER+ breast cancer with Ibrutinib for personalized precision medicine: a double-edged sword. , 2017, , .		0
35	NUT Midline Carcinoma Masquerading As a Thymic Carcinoma. Journal of Clinical Oncology, 2016, 34, e126-e129.	1.6	6
36	Role of tumor infiltrating lymphocytes (TILs) in HER2+ metastatic breast cancers (MBC) treated with trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine (L+C) (EMILIA Trial).. Journal of Clinical Oncology, 2016, 34, 607-607.	1.6	2

#	Article	IF	Citations
37	Upregulation of HSF1 in estrogen receptor positive breast cancer. Oncotarget, 2016, 7, 84239-84245.	1.8	24
38	Identification of novel immunomodulatory tumor biology through comprehensive characterization of a metastases-specific epigenome in patients with metachronous primary and metastatic urothelial carcinoma (UC) tumor pairs.. Journal of Clinical Oncology, 2016, 34, 452-452.	1.6	20
39	Alternative Splicing in Breast Cancer. , 2016, , 365-377.		0
40	Noncoding RNAs in Breast Cancer. , 2016, , 345-364.		0
41	Abstract P2-06-05: LINC00478: A novel tumor suppressor in breast cancer. , 2016, , .		2
42	RespondR signature to predict response in TNBC patients treated with adjuvant taxane based chemotherapy in TCGA dataset.. Journal of Clinical Oncology, 2016, 34, 1079-1079.	1.6	2
43	RespondR signature to predict potential alternative therapies for taxane resistant triple-negative breast cancer patients.. Journal of Clinical Oncology, 2016, 34, 1078-1078.	1.6	1
44	Tumor Heterogeneity in Breast Cancer. Advances in Anatomic Pathology, 2015, 22, 294-302.	4.3	12
45	Prognostic Impact of HOTAIR Expression is Restricted to ER-Negative Breast Cancers. Scientific Reports, 2015, 5, 8765.	3.3	55
46	2648 Novel DNA methylation therapeutic targets in urothelial carcinoma (UC) from patients with paired metachronous primary and metastatic tumors. European Journal of Cancer, 2015, 51, S529.	2.8	0
47	Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients. Journal of Neuro-Oncology, 2015, 122, 205-216.	2.9	31
48	Single-cell screening and quantification of transcripts in cancer tissues by second-harmonic generation microscopy. Journal of Biomedical Optics, 2015, 20, 096016.	2.6	5
49	Micronodular thymic neoplasms: case series and literature review with emphasis on the spectrum of differentiation. Modern Pathology, 2015, 28, 1415-1427.	5.5	36
50	Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer. Modern Pathology, 2015, 28, 677-685.	5.5	28
51	Role of lncRNAs in health and disease--size and shape matter. Briefings in Functional Genomics, 2015, 14, 115-129.	2.7	28
52	Abstract P3-05-20: ESRP1 adds sp(l)ice to endocrine resistance. , 2015, , .		0
53	Abstract PD1-7: Differential expression of innate and adaptive immune responses in TNBC outcome. , 2015, , .		0
54	RespondR: A genomic score to predict the responsiveness of triple-negative breast cancer patients to chemotherapy.. Journal of Clinical Oncology, 2015, 33, 1020-1020.	1.6	0

#	Article	IF	Citations
55	Breast cancer prognostic markers: an overview of a changing menu. Medical Laboratory Observer, 2015, 47, 8, 10, 12-3; quiz 14.	0.1	1
56	Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer. Journal of Cancer, 2014, 5, 633-645.	2.5	9
57	The prognostic value of architectural patterns in a study of 37 type AB thymomas. Modern Pathology, 2014, 27, 863-868.	5.5	7
58	NUT midline carcinomas in the thymic region. Modern Pathology, 2014, 27, 1649-1656.	5.5	12
59	Multiplexed Protein Analysis. Science Translational Medicine, 2014, 6, 219fs3.	12.4	4
60	Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines. Clinical and Experimental Metastasis, 2014, 31, 771-786.	3.3	33
61	DNA Double-Strand Break Repair Genes and Oxidative Damage in Brain Metastasis of Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	6.3	57
62	INDUCT: A risk score to predict relapse in estrogen-receptorâ€“positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 11063-11063.	1.6	1
63	Prognostic ability of CD44 expression in ER-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, 11062-11062.	1.6	0
64	Abstract 4187: Splicing factorsESRP1/ESRP2as regulators of endocrine resistance in breast cancer. , 2014, , .		0
65	Counterpoint: Cancer Stem Cells: Nonbelievers' Viewpoint. Clinical Chemistry, 2013, 59, 208-210.	3.2	2
66	FOXP3 expression and nodal metastasis of breast cancer. Cellular Oncology (Dordrecht), 2013, 36, 405-409.	4.4	6
67	The role of histology in predicting recurrence of type A thymomas: a clinicopathologic correlation of 23 cases. Modern Pathology, 2013, 26, 1059-1064.	5.5	45
68	A Gene Signature to Determine Metastatic Behavior in Thymomas. PLoS ONE, 2013, 8, e66047.	2.5	31
69	A gene signature to determine metastatic behavior in thymic carcinoma.. Journal of Clinical Oncology, 2013, 31, 7605-7605.	1.6	0
70	Abstract P5-09-09: ESRP1 and ESRP2 expression in tamoxifen resistance. , 2013, , .		0
71	Extrathoracic metastases of thymic origin: a review of 35 cases. Modern Pathology, 2012, 25, 370-377.	5.5	63
72	Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models. Breast Cancer Research and Treatment, 2012, 136, 673-682.	2.5	73

#	Article	IF	Citations
73	Establishment and characterization of a novel cell line derived from human thymoma AB tumor. Laboratory Investigation, 2012, 92, 1564-1573.	3.7	24
74	13-gene signature to predict rapid development of brain metastases in patients with HER2-positive advanced breast cancer.. Journal of Clinical Oncology, 2012, 30, 505-505.	1.6	7
75	Molecular Analysis of Thymoma. PLoS ONE, 2012, 7, e42669.	2.5	37
76	Abstract 4206: Identification of transcriptional regulatory motifs that control gene expression in premenopausal women with previous history of breast cancer. , 2012, , .		0
77	In silico identification of an epithelial core signature in human tumors.. Journal of Clinical Oncology, 2012, 30, 10628-10628.	1.6	0
78	A 19-gene prognostic GEP signature (DecisionDx-Thymoma) to determine metastatic risk associated with thymomas.. Journal of Clinical Oncology, 2012, 30, 7106-7106.	1.6	1
79	A 19-gene prognostic GEP signature to determine metastatic risk associated with thymomas.. Journal of Clinical Oncology, 2012, 30, 68-68.	1.6	0
80	Molecular profiling assays in breast cancer: are we ready for prime time?. Oncology, 2012, 26, 350-7, 361.	0.5	16
81	Breast cancer prognostic markers: where are we now?. Medical Laboratory Observer, 2012, 44, 22, 24-5.	0.1	2
82	Biomarkers for breast cancer stem cells: the challenges ahead. Biomarkers in Medicine, 2011, 5, 661-671.	1.4	17
83	Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Research and Treatment, 2011, 127, 375-384.	2.5	37
84	Tumor marker assessment: Points to ponder. Cancer Biology and Therapy, 2011, 11, 284-286.	3.4	1
85	Abstract 3489: In silico analysis of angiogenesis pathway as a prognostic tool in breast cancer. , 2011, , .		0
86	RAD51 and brain metastases (BM) in patients (pts) with HER2+ breast cancer.. Journal of Clinical Oncology, 2011, 29, 634-634.	1.6	2
87	P3-04-02: Bevacizumab Treatment Alters Intrinsic Subtypes in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer.. , 2011, , .		0
88	P5-06-01: Gene Expression Analysis of Resistance to Bevacizumab in a VEGF-Reinforced Xenograft Model of ER-Positive Breast Cancer.. , 2011, , .		0
89	P2-13-01: Gene Profiling of Whole Blood May Identify Patients with BRCA Mutations.. , 2011, , .		0
90	Promise of computational systems biology for cancer clinical trials: the voyage to be realized?. Personalized Medicine, 2010, 7, 129-131.	1.5	2

#	Article	IF	Citations
91	Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Breast Cancer Research and Treatment, 2010, 124, 327-335.	2.5	16
92	Redefining the Target Again: Chemotherapeutics as Vascular Disrupting Agents?. Cancer Cell, 2008, 14, 195-196.	16.8	11
93	2-Methoxyestradiol Inhibits the Anaphase-Promoting Complex and Protein Translation in Human Breast Cancer Cells. Cancer Research, 2007, 67, 702-708.	0.9	24
94	A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells. Proteomics - Clinical Applications, 2007, 1, 18-31.	1.6	6
95	Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate, 2006, 66, 1498-1511.	2.3	44
96	Protein Kinase C-Î² as a Therapeutic Target in Breast Cancer. Seminars in Oncology, 2006, 33, 15-18.	2.2	41
97	Î²-Tubulin Mutations Are Associated with Resistance to 2-Methoxyestradiol in MDA-MB-435 Cancer Cells. Cancer Research, 2005, 65, 9406-9414.	0.9	36
98	Protein kinase CÎ¹ is required for Ras transformation and colon carcinogenesis in vivo. Journal of Cell Biology, 2004, 164, 797-802.	5.2	129
99	EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Research, 2003, 63, 3425-9.	0.9	56
100	Mapping of a Molecular Determinant for Protein Kinase C Î²II Isozyme Function. Journal of Biological Chemistry, 1998, 273, 20261-20266.	3.4	46
101	Wortmannin converts insulin but not oxytocin from an antilipolytic to a lipolytic agent in the presence of forskolin. Metabolism: Clinical and Experimental, 1997, 46, 62-66.	3.4	3
102	Inhibition by NMDA of carbachol-stimulated inositol tetrakisphosphate accumulation in rat brain cortical slices. Neuropharmacology, 1996, 35, 415-421.	4.1	1
103	Insulin sensitizes beta-agonist and forskolin-stimulated lipolysis to inhibition by 2',5'-dideoxyadenosine. American Journal of Physiology - Cell Physiology, 1996, 270, C562-C569.	4.6	9
104	Enhanced desensitization and phosphorylation of the beta 1-adrenergic receptor in rat adipocytes by peroxovanadate. Molecular Pharmacology, 1996, 49, 1049-57.	2.3	11
105	Inhibition by veratridine of carbachol-stimulated inositol tetrakisphosphate accumulation in rat brain cortical slices. Neurochemical Research, 1995, 20, 1057-1064.	3.3	1
106	Polymorphisms associated with the FVIII and FIX genes in the Turkish population. Haemophilia, 1995, 1, 184-189.	2.1	10